Neuroprotective effect of baicalein against MPTP neurotoxicity: Behavioral, biochemical and immunohistochemical profile

Neuroscience Letters

Volumn 441, Issue 1, 2008, Pages 16-20

  Cheng, Yinxia ^a   He, Guorong ^a   Mu, Xin ^a   Zhang, Tiantai ^a   Li, Xiaoxiu ^a   Hu, Juanjuan ^a   Xu, Bei ^a   Du, Guanhua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Baicalein; Neuroprotective; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BAICALEIN; DOPAMINE; SEROTONIN;

ABNORMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BIOCHEMISTRY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INTOXICATION; MACROGLIA; MALE; MOTOR ACTIVITY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CELL COUNT; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG INTERACTIONS; FLAVANONES; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROPROTECTIVE AGENTS; PSYCHOMOTOR PERFORMANCE; TYROSINE 3-MONOOXYGENASE;

EID: 46149119392     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.05.116     Document Type: Article

References (24)

1. Arai N., Misugi K., Goshima Y., and Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 515 (1990) 57-63
2. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
3. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
4. Franco-Maside A., Vinagre D., Caamano J., Alvarez X.A., Fernandez-Novoa L., Novo B., Zas R., Gomez M.J., and Cacabelos R. Brain electrical activity in neurogerontology and psychogeriatric disorders. Methods Find. Exp. Clin. Pharmacol. 17 (1995) 207-224
5. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69 (1997) 1322-1325
6. Gao Z., Huang K., and Xu H. Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacol. Res. 43 (2001) 173-178
7. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 193 (2005) 279-290
8. Hornykiewicz O., and Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45 (1987) 19-34
9. Im H.I., Joo W.S., Nam E., Lee E.S., Hwang Y.J., and Kim Y.S. Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice. J. Pharmacol. Sci. 98 (2005) 185-189
10. Kato H., Kurosaki R., Oki C., and Araki T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res. 1030 (2004) 66-73
11. Lebeau A., Esclaire F., Rostene W., and Pelaprat D. Baicalein protects cortical neurons from beta-amyloid (25-35) induced toxicity. Neuroreport 12 (2001) 2199-2202
12. LeWitt P.A. New drugs for the treatment of Parkinson's disease. Pharmacotherapy 20 (2000) 26S-32S
13. Li F.Q., Wang T., Pei Z., Liu B., and Hong J.S. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. J. Neural Transm. 112 (2005) 331-347
14. Lin C.C., and Shieh D.E. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am. J. Chin. Med. 24 (1996) 31-36
15. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275 (2000) 38581-38588
16. Mendis T., Suchowersky O., Lang A., and Gauthier S. Management of Parkinson's disease a review of current and new therapies. Can. J. Neurol. Sci. 26 (1999) 89-103
17. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 51 (1998) S25-29
18. Ridet J.L., Malhotra S.K., Privat A., and Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20 (1997) 570-577
19. Sharma V., Mishra M., Ghosh S., Tewari R., Basu A., Seth P., and Sen E. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res. Bull. 73 (2007) 55-63
20. Shieh D.E., Liu L.T., and Lin C.C. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 20 (2000) 2861-2865
21. Stromberg I., Bjorklund H., Dahl D., Jonsson G., Sundstrom E., and Olson L. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res. Bull. 17 (1986) 225-236
22. Sundstrom E., Fredriksson A., and Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res. 528 (1990) 181-188
23. Tipton K.F., and Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61 (1993) 1191-1206
24. Zatta P., Zambenedetti P., and Milanese M. Activation of monoamine oxidase type-B by aluminum in rat brain homogenate. Neuroreport 10 (1999) 3645-3648